Cinnamide chemokine CCR3 antagonists

Abstract

Two applications from Novartis describe a novel structural class of chemokine CCR3 antagonists. Both applications describe N-(4-aryloxypiperidiny1-ylalkyl) cinnamide derivatives and only differ in whether the alkyl linking group is linear or branched bearing an additional functional substituent. Both sets of derivatives provide low nanomolar affinity antagonists.

• antagonist
• asthma
• CCR3
• eosinophil
• eotaxin